Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
minimal residual disease
MedTech
Natera buys Foresight Diagnostics in $450M cancer testing deal
Natera has closed the transaction, which features an upfront payment of $275 million plus as much as $175 million in milestones.
Conor Hale
Dec 5, 2025 11:57am
Roche sues Stanford, Foresight Diagnostics over trade secrets
Jul 3, 2024 10:44am
JPM24: Veracyte inks $95M deal to buy C2i Genomics
Jan 9, 2024 10:22am
ASCO: Inside C2i Genomics' precision oncology 'one-stop shop'
Jun 3, 2023 10:34pm
Quest pens $450M deal for cancer test maker Haystack Oncology
Apr 27, 2023 9:25am
